Breaking News Instant updates and real-time market news.

SSNLF

Samsung

, RHHBY

Roche

$30.96

-0.01 (-0.03%)

09:17
10/04/16
10/04
09:17
10/04/16
09:17

Samsung BioLogics could be valued above $8B in IPO, WSJ reports

Samsung BioLogics, which is 47.8% owned by the Samsung Electronics (SSNLF), stated in a regulatory filing that it would sell 16.5M shares to raise $1.7B-$2B in an initial public offering, valuing the company at as much as $8.2B, reported The Wall Street Journal. Separately, a subsidiary of Samsung BioLogics, Samsung Bioepis, said that it had submitted a biosimilar version of breast-cancer drug Herceptin for regulatory approval in Europe. If approved, Samsung would sell its biosimilar version of Herceptin, a drug developed by a unit of Roche (RHHBY), through Merck (MRK), the report noted. In late August, Mylan (MYL) and Biocon submitted the first application for European approval of a Herceptin biosimilar. Reference Link

SSNLF

Samsung

RHHBY

Roche

$30.96

-0.01 (-0.03%)

MRK

Merck

MYL

Mylan

$38.20

0.08 (0.21%)

  • 07

    Oct

  • 19

    Oct

  • 23

    Oct

  • 25

    Oct

  • 06

    Nov

  • 10

    Nov

  • 28

    Mar

SSNLF Samsung

08/01/16
NEED
08/01/16
NO CHANGE
Target $65
NEED
Buy
Synaptics price target lowered to $65 from $88 at Needham
Needham analyst Rajvindra Gill lowered his price target for Synaptics (SYNA) to $65 from $88 on a lower earnings multiple as he remains uncertain on whether the company has secured the OLED DDIC for Apple's (AAPL) iPhone 8 versus an internal Samsung (SSNLF) solution. The analyst reiterates a Buy rating on Synaptics' shares, saying the company will remain one of the leaders in the display markets.
06/23/16
BFIN
06/23/16
NO CHANGE
BFIN
Fitbit faces 'fight of its life,' GoPro Karma delay a problem, says BlueFin
In an update on the wearable space, BlueFin analysts John Donovan and Steve Mullane make the case that Fitbit (FIT) is "in for the fight of its life" given mounting competition that is coming from Samsung (SSNLF), Apple (AAPL), Garmin (GRMN) and Under Armour (UA), adding that the sizable inventory of Alta and Blaze devices that it must deplete in this competitive environment puts Fitbit is in a "precarious position." The analyst add that Apple's watchOS improvements "further paint Fitbit into a corner," but noted that market data suggests consumers are looking for wearables under $200, which is in the "sweet spot" of Fitbit's portfolio. Weighing in on GoPro (GPRO), the analysts wonder if the Hero5 will be compelling enough to make consumers buy another camera and note that its upcoming Karma drone is very late to market and "facing daunting odds."
04/26/16
NEED
04/26/16
NO CHANGE
NEED
Apple supply chain names to rebound, says Needham
Needham analyst Rajvindra Gill expects a rebound in the Apple (AAPL) supply chain names given its underperformance over the last 25 days and the relatively good quarterly results from Knowles (KN). Among the names, the analyst sees Cirrus Logic (CRUS) increasing its dollar content per unit about 40% for the iPhone 7 cycle, with possible upside of 80%-100% for the iPhone 7S in 2017 with the inclusion of adaptive noise cancellation. Knowles, which generated 25% of sales from Apple and less than 10% of sales from Samsung (SSNLF), posted better-than-expected results and guidance, the analyst tells investors in a research note.
04/13/16
ROTH
04/13/16
NO CHANGE
Target $2.6
ROTH
Buy
Digital Turbine estimates, price target reduced at Roth Capital
Roth Capital analyst Brian Alger reduced his estimates for Digital Turbine (APPS) and lowered his price target on the shares to $2.60 from $3, after the company quantified the miss that it had previewed last month. The shortfall was attributed to the slashed digital ad budget of a large advertising customer, Verizon (VZ) choosing to reduce the number of slots per device for much of the March quarter, and to Verizon Samsung S7's (SSNLF) that have yet to have Ignite software included, the analyst tells investors in a research note. Alger reiterates a Buy rating on Digital Turbine's shares, considering the depressed current valuation.
RHHBY Roche
$30.96

-0.01 (-0.03%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
MRK Merck

10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
MYL Mylan
$38.20

0.08 (0.21%)

10/04/16
JPMS
10/04/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan price target lowered to $52 from $62 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Mylan to $52 saying he remains cautious on the shares over the near-term given the ongoing Epipen controversy. The analyst, however, views the stock as "very inexpensive" and keeps an Overweight rating on the name. Schott sees a limited long-term impact to his thesis from the Epipen controversy and believes Mylan's generics business is underappreciated. He maintains an Overweight rating on the shares.
09/30/16
LEER
09/30/16
NO CHANGE
Target $45
LEER
Outperform
Mylan price target cut to $45 on lower EpiPen estimates at Leerink
Leerink analyst Jason Gerberry lowered his EpiPen sales forecasts by 33-45% from 2017-2021 in light of recent company updates, including its plan to launch an authorized generic of the emergency treatment later this year. While Mylan "appears on the right side of the law" regarding the latest Medicaid rebate controversy, Gerberry believes investors should consider the risk of a future settlement related to the issue. He cut his price target on Mylan shares to $45 from $55, but keeps an Outperform rating on the stock as he sees cash flows being sufficient to justify the current price.
09/23/16
BERN
09/23/16
NO CHANGE
BERN
Mylan generic Epipen to lower EPS by about 10%, says Bernstein
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
09/22/16
ARGS
09/22/16
NO CHANGE
ARGS
Mylan weakness creates good entry point, says Argus
After Mylan's stock fell 17% over the last month, Argus analyst Jacob Kilstein thinks that the stock has reached an attractive entry point, He says that the company's new generic EpiPen will cannibalize branded sales but should help it beat upcoming generic competitors. He thinks that the stock is undervalued and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

VDNRF

Vedanta Resources

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Downgrade
Vedanta Resources rating change  »

Vedanta Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPE

Expedia

$134.14

2.16 (1.64%)

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Options
Notable pre-earnings option play in Expedia »

Notable pre-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

10:40
04/25/17
04/25
10:40
04/25/17
10:40
General news
Treasury Option Action: a round of positioning »

Treasury Option Action: a…

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:39
04/25/17
04/25
10:39
04/25/17
10:39
Hot Stocks
JetBlue says fleet review 'going to take a little bit of time' »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

, SSNLF

Samsung

10:38
04/25/17
04/25
10:38
04/25/17
10:38
Periodicals
Samsung to give new MRAM memory details next month, Patently Apple says »

Following on a report…

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

SSNLF

Samsung

IBM

IBM

$161.45

0.7 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

AVXS

AveXis

$79.18

2.42 (3.15%)

10:37
04/25/17
04/25
10:37
04/25/17
10:37
Hot Stocks
AveXis says AVXS-101 appears to have favorable safety profile in Phase 1 trial »

AveXis presented results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

TSLA

Tesla

$308.03

2.43 (0.80%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Periodicals
Union workers claim Tesla illegally intimidated them, BuzzFeed says »

The United Automobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

AEP

American Electric

$67.86

-0.11 (-0.16%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Hot Stocks
American Electric says to invest $17.3B in capital over next three years »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

10:35
04/25/17
04/25
10:35
04/25/17
10:35
General news
U.S. consumer confidence fell to a still-robust 120.3 »

U.S. consumer confidence…

FCX

Freeport McMoRan

$13.19

0.955 (7.81%)

10:34
04/25/17
04/25
10:34
04/25/17
10:34
Hot Stocks
Freeport McMoRan says near-term debt situation ins manageable »

At some point looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Hot Stocks
JetBlue says early A321NEOs have Pratt & Whitney GTF engines »

JetBlue says "We…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

UTX

United Technologies

$117.06

0.74 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

BIIB

Biogen

$276.86

3.92 (1.44%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Recommendations
Biogen analyst commentary  »

With Spinraza 'just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

UNXL

Uni-Pixel

$0.80

-0.01 (-1.23%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Options
Uni Pixel with higher call volume »

Uni Pixel with higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

10:30
04/25/17
04/25
10:30
04/25/17
10:30
General news
The 5.8% March U.S. new home sales surge »

The 5.8% March U.S. new…

EAT

Brinker

$43.93

-1.53 (-3.37%)

10:29
04/25/17
04/25
10:29
04/25/17
10:29
Hot Stocks
Brinker says 'comfortable' with guidance provided for FY17 »

Management said on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

JBLU

JetBlue

$21.75

0.22 (1.02%)

10:28
04/25/17
04/25
10:28
04/25/17
10:28
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue says committed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on JetBlue, Embraer »

JetBlue says timing…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

QQQ

PowerShares QQQ Trust

$134.16

1.6 (1.21%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Technical Analysis
PowerShares QQQ Trust hits fresh 52-week highs »

The breakout that began…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

C

Citi

$60.29

0.85 (1.43%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Citi confirms receipt of CMA license in Saudi Arabia »

The Saudi Arabian Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

  • 25

    Jul

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
JetBlue aiming for CASM ex-fuel flat to up 1% for 2018-2020 »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BBRY

BlackBerry

$9.29

0.21 (2.31%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$81.41

-2.01 (-2.41%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Eli Lilly says hasn't contemplated scenario to not pursue baricitinib in RA »

On Eli Lilly's Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

10:25
04/25/17
04/25
10:25
04/25/17
10:25
General news
U.S. Richmond Fed manufacturing index dipped to 20 in April »

U.S. Richmond Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.